Universal Biosensors (ASX:UBI) share price up on "global first" 30-second COVID-19 test

This micro-cap biotech has big news for ASX investors today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Universal Biosensors Inc (ASX: UBI) share price is in the green after the company announced a licensing deal to commercialise a new rapid COVID-19 test.

Shares in the biotech are swapping hands for 89 cents at the time of writing, up 0.57%. Shortly after the market open, the share price jumped to an intraday high thus far of 94 cents. This is 6.8% higher than yesterday's close.

Let's take a look at the news driving positive investor sentiment today.

A female scientist sits at a microscope in a Universal Biosensors laboratory smiling while her colleague checks beakers of COVID-19 samples in the background.

Image source: Getty Images

What is impacting the Universal Biosensors share price?

Universal Biosensors informed ASX investors that it has signed a deal with IQ Science Limited. The deal will commercialise a new rapid COVID-19 test.

The SARS-CoV-2 N-protein detection test will use the company's electrochemical strip and device technology.

Initial internal validation work found the COVID-19 test can detect the virus within just 30 seconds.

Universal Biosensors has been working with IQ Science founder Dr Shalen Kumar on the technology for 6 months.

The licensing agreement is globally exclusive. Commercialisation fees will be paid either after the test gains regulatory approval, or when the test generates $1 million in sales.

Universal Biosensors will manage funding for the project and gaining all the regulatory approvals required to commercialise the test. If the test is not taken to the market within the next 5 years, the licence will become non-exclusive.

Management comment

Commenting on the COVID-19 test agreement, Universal Biosensors CEO John Sharman said:

The deal with IQ Science is an important breakthrough for UBI since it will be the first time our platform will use aptamers as a detection technique.

Aptamers are a next generation biorecognition element which when combined with our existing technology platform should allow us to detect and measure a large number of targets.

Based on what we know is available in the world today, a COVID-19 Test offering an accurate result within 30 seconds of the patient sample will be the first of its kind globally.

Universal Biosensors share price snapshot

The Universal Biosensors share price has surged by roughly 106% in the past 12 months. For perspective, the S&P/ASX 200 Index (ASX: XJO) is up by more than 11% over the same period.

The company has a market capitalisation of roughly $159 million based on its current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »